—

annul Commission’s Implementing Decision C (2019)5393 final of 11 July 2019 refusing marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council (1) for ‘Cabazitaxel Teva – cabazitaxel’ (‘the decision’) insofar as it applies to the applicant, and

—

order the defendants to pay the applicant’s costs.

1.

First plea in law, alleging that the Commission failed correctly to apply the concept of a ‘global marketing authorisation’ within the meaning of Directive 2001/83 of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001, L 311, p. 67), in particular the concept of a ‘derivative’ medicinal product in Article 10(2)(b) thereof.

2.

Second plea in law, alleging that the Commission and the EMA breached the principle of procedural fairness and the applicant’s right to good administration, in particular by reversing the burden of proof on generic applicants for marketing authorisations contrary to the requirements of the EU legislation in this field.

3.

Third plea in law, alleging that by this conduct, the Commission also breached the principle of equal treatment, by treating the applicant differently to the holder of the marketing authorisation for Jevtana®/docetaxel.